Market Size of Hyperkalemia Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 16.79 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Hyperkalemia Treatment Market Analysis
The hyperkalemia treatment market is poised to register a CAGR of 16.79% over the forecast period.
The COVID-19 pandemic impacted the market significantly during the pandemic phase. Since the beginning of the pandemic, there have been numerous discussions regarding the impact of COVID-19 on several areas of human health, and hyperkalemia is no exception. Several scientists conducted observational studies to find the correlation between hyperkalemia and COVID-19. For instance, according to an article published by PubMed in August 2021, there have been numerous reports of electrolyte issues, notably potassium imbalances, as frequent clinical symptoms of COVID-19. In this research, scientists have explored how SARS-CoV-2 may alter potassium homeostasis by reducing epithelial sodium channels' activity (ENaC) and explained the prevalence of hypokalemia. and concluded that there is a correlation between COVID-19 and hyperkalemia. Thus, the use of drugs to treat hyperkalemia increased during the pandemic. However, as the pandemic has subsided currently, the market is expected to have stable growth during the forecast period of the study.
Factors such as the increasing prevalence of hyperkalemia, the rising focus on research and development, and an increasing number of strategic alliances among major market players are anticipated to drive the market's growth. For instance, the article published by Healthline in March 2022 stated that high potassium levels, or hyperkalemia (HK), affect 40% to 50% of people with chronic kidney disease (CKD) globally, and nearly 40% of people with congestive heart failure (CHF) develop high potassium levels.
In addition, another article published by PubMed Central in October 2021 stated that when the research was conducted to characterize the progression of HK and identify the risk factors for HK progression, greater rates of HK progression were observed in individuals with advanced CKD stages, while higher potassium levels were also found among heart failure, hypertension, and diabetes patients. Such disease prevalence is expected to necessitate the availability of drugs and diagnostics to the target population, contributing to the market's growth.
Therefore, owing to the above-mentioned factors, such as the increasing prevalence of hyperkalemia and the rising focus on research and development, the market studied is expected to grow over the forecast period. However, the high cost of drugs is anticipated to hinder market growth over the forecast period.
